- Home
- FTHM vs IGC Comparison
FTHM vs IGC Comparison
Compare FTHM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | IGC |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 31.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTHM | IGC |
|---|---|---|
| Price | $1.06 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $4.13 |
| AVG Volume (30 Days) | 82.6K | ★ 936.3K |
| Earning Date | 11-11-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $421,612,000.00 | $1,106,000.00 |
| Revenue This Year | $30.07 | $3.54 |
| Revenue Next Year | $14.66 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.78 | N/A |
| 52 Week Low | $0.65 | $0.25 |
| 52 Week High | $3.37 | $0.50 |
Technical Indicators
Market Signals| Indicator | FTHM | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 36.62 |
| Support Level | $0.98 | $0.29 |
| Resistance Level | $1.15 | $0.31 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 27.59 | 12.00 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.